In order to see if the tumor cell-impacting effect of the dual epigenetic inhibitor CM-272 can also be reached by inhibiting just one epigenetic mechanism, being either DNA demethylation or histone methylation (Figure 2C), we applied the demethylating agent 5-azacytidine as well as the specific inhibitor of G9a histone methyltransferase BIX-01294 to our drug testing platform. Here, EHMT2 is linked to neoplasm.